Evotec (EVO) Competitors $4.34 +0.12 (+2.84%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$4.43 +0.09 (+2.07%) As of 04:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVO vs. TGTX, NUVL, LNTH, TLX, AXSM, AKRO, ADMA, PCVX, KRYS, and RYTMShould you be buying Evotec stock or one of its competitors? The main competitors of Evotec include TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), ADMA Biologics (ADMA), Vaxcyte (PCVX), Krystal Biotech (KRYS), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry. Evotec vs. Its Competitors TG Therapeutics Nuvalent Lantheus Telix Pharmaceuticals Axsome Therapeutics Akero Therapeutics ADMA Biologics Vaxcyte Krystal Biotech Rhythm Pharmaceuticals TG Therapeutics (NASDAQ:TGTX) and Evotec (NASDAQ:EVO) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations. Which has more risk & volatility, TGTX or EVO? TG Therapeutics has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500. Comparatively, Evotec has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500. Does the media refer more to TGTX or EVO? In the previous week, TG Therapeutics had 8 more articles in the media than Evotec. MarketBeat recorded 9 mentions for TG Therapeutics and 1 mentions for Evotec. Evotec's average media sentiment score of 1.02 beat TG Therapeutics' score of 0.83 indicating that Evotec is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evotec 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in TGTX or EVO? 58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 10.6% of TG Therapeutics shares are owned by company insiders. Comparatively, 1.0% of Evotec shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts prefer TGTX or EVO? TG Therapeutics presently has a consensus price target of $40.80, suggesting a potential upside of 12.43%. Evotec has a consensus price target of $5.93, suggesting a potential upside of 36.71%. Given Evotec's higher possible upside, analysts plainly believe Evotec is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Evotec 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Which has higher valuation & earnings, TGTX or EVO? TG Therapeutics has higher earnings, but lower revenue than Evotec. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTG Therapeutics$329M17.51$23.38M$0.24151.21Evotec$862.40M1.79-$212.18MN/AN/A Is TGTX or EVO more profitable? TG Therapeutics has a net margin of 10.13% compared to Evotec's net margin of -26.34%. TG Therapeutics' return on equity of 18.88% beat Evotec's return on equity.Company Net Margins Return on Equity Return on Assets TG Therapeutics10.13% 18.88% 7.05% Evotec -26.34%-21.51%-10.54% SummaryTG Therapeutics beats Evotec on 11 of the 14 factors compared between the two stocks. Get Evotec News Delivered to You Automatically Sign up to receive the latest news and ratings for EVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVO vs. The Competition Export to ExcelMetricEvotecMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.50B$2.42B$5.54B$8.87BDividend YieldN/A1.77%5.39%4.10%P/E RatioN/A8.8326.1719.90Price / Sales1.79663.86413.55113.66Price / CashN/A151.5836.1356.90Price / Book1.494.548.025.38Net Income-$212.18M$31.16M$3.15B$248.50M7 Day Performance2.84%0.07%1.48%2.06%1 Month Performance7.69%7.24%3.66%4.86%1 Year Performance-15.73%1.37%34.68%20.24% Evotec Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVOEvotec1.6537 of 5 stars$4.34+2.8%$5.93+36.7%-12.3%$1.50B$862.40M0.004,827Positive NewsTGTXTG Therapeutics3.7706 of 5 stars$35.99-2.0%$40.80+13.4%+98.2%$5.83B$329M149.96290NUVLNuvalent3.736 of 5 stars$76.30-4.2%$119.60+56.7%+10.3%$5.72BN/A-17.3840Analyst UpgradeInsider TradeLNTHLantheus4.4515 of 5 stars$81.86+0.5%$130.50+59.4%+1.4%$5.64B$1.53B23.26700Positive NewsTLXTelix PharmaceuticalsN/A$16.07+0.4%$22.00+36.9%N/A$5.41B$516.72M0.00N/AGap DownAXSMAxsome Therapeutics4.6788 of 5 stars$104.39+1.0%$172.33+65.1%+31.6%$5.09B$385.69M-18.09380Analyst RevisionAKROAkero Therapeutics3.6296 of 5 stars$53.36-5.0%$82.50+54.6%+131.8%$4.48BN/A-27.3630ADMAADMA Biologics4.1061 of 5 stars$18.21+0.3%$27.67+51.9%+59.1%$4.34B$426.45M21.42530PCVXVaxcyte1.8037 of 5 stars$32.51-0.2%$136.50+319.9%-56.3%$4.20BN/A-8.15160News CoveragePositive NewsKRYSKrystal Biotech4.5544 of 5 stars$137.46-1.0%$211.13+53.6%-20.4%$4.01B$290.52M33.04210News CoverageAnalyst RevisionRYTMRhythm Pharmaceuticals3.7995 of 5 stars$63.19+0.7%$77.31+22.3%+58.1%$3.99B$130.13M-22.49140 Related Companies and Tools Related Companies TG Therapeutics Alternatives Nuvalent Alternatives Lantheus Alternatives Telix Pharmaceuticals Alternatives Axsome Therapeutics Alternatives Akero Therapeutics Alternatives ADMA Biologics Alternatives Vaxcyte Alternatives Krystal Biotech Alternatives Rhythm Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVO) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evotec AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Evotec With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.